Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cisplatin; Fluorouracil; Gemcitabine; Mitomycin
Indications Bladder cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-992; MK-3475-992/KEYNOTE-992
Sponsors Merck Sharp & Dohme Corp.

25 Nov 2024 Planned End Date changed from 10 Jun 2031 to 1 Nov 2031.
05 Nov 2024 Planned number of patients changed from 636 to 520.
05 Nov 2024 Planned primary completion date changed from 10 Jun 2029 to 31 Jan 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com